NCT06395103 2026-04-13
MK-9999-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
Clinical Trials
8 trialsNCT07502287 2026-03-30
DUAL-NK-NB
Beijing Biotech
Phase 1/2 Recruiting
NCT03363373 2026-02-19
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Y-mAbs Therapeutics
Phase 2 Recruiting
NCT05642455 2026-02-09
SPEARHEAD-3 Pediatric Study
USWM, LLC (dba US WorldMeds)
Phase 1/2 Recruiting
NCT04337177 2025-09-23
Flavored, Oral Irinotecan VAL-413 (OrotecanĀ®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies, LLC
Phase 1 Recruiting
NCT06674265 2025-04-09
Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma
Kian Immune Cell Company
Phase 1 Recruiting
NCT05701306 2025-02-25
APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors
Ascentage Pharma Group Inc.
Phase 1 Recruiting
NCT04253015 2024-02-07
A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta
RECORDATI GROUP
Recruiting